These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35583460)
21. COVID-19: Progress in diagnostics, therapy and vaccination. Liu X; Liu C; Liu G; Luo W; Xia N Theranostics; 2020; 10(17):7821-7835. PubMed ID: 32685022 [TBL] [Abstract][Full Text] [Related]
22. Current Status of Diagnostic Testing for SARS-CoV-2 Infection and Future Developments: A Review. Gao J; Quan L Med Sci Monit; 2020 Dec; 26():e928552. PubMed ID: 33332288 [TBL] [Abstract][Full Text] [Related]
23. COVID-19 Vaccine: A comprehensive status report. Kaur SP; Gupta V Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805 [TBL] [Abstract][Full Text] [Related]
24. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Russell RL; Pelka P; Mark BL Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067 [TBL] [Abstract][Full Text] [Related]
25. [Research and application of the SARS-CoV-2 vaccine based on adenovirus vector technology platform]. Zhang Y; Yu WZ; Yin ZD; Wang TZ; Sun XD; Xu AQ Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jul; 57(7):1082-1095. PubMed ID: 37198717 [TBL] [Abstract][Full Text] [Related]
26. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. He X; He C; Hong W; Yang J; Wei X Med Res Rev; 2023 Jul; 43(4):932-971. PubMed ID: 36929527 [TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 vaccine candidates in rapid development. Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319 [TBL] [Abstract][Full Text] [Related]
28. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. Hosseini SA; Zahedipour F; Mirzaei H; Kazemi Oskuee R Int Immunopharmacol; 2021 Aug; 97():107622. PubMed ID: 33895475 [TBL] [Abstract][Full Text] [Related]
29. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries. Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Dhama K; Patel SK; Sharun K; Pathak M; Tiwari R; Yatoo MI; Malik YS; Sah R; Rabaan AA; Panwar PK; Singh KP; Michalak I; Chaicumpa W; Martinez-Pulgarin DF; Bonilla-Aldana DK; Rodriguez-Morales AJ Travel Med Infect Dis; 2020; 37():101830. PubMed ID: 32755673 [TBL] [Abstract][Full Text] [Related]
32. Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures. Wang J; Xie Q; Song H; Chen X; Zhang X; Zhao X; Hao Y; Zhang Y; Li H; Li N; Fan K; Wang X J Nanobiotechnology; 2023 Jun; 21(1):200. PubMed ID: 37344839 [TBL] [Abstract][Full Text] [Related]
33. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585 [TBL] [Abstract][Full Text] [Related]
34. Next-Generation Vaccine Development with Nanomaterials: Recent Advances, Possibilities, and Challenges. Shetty S; Alvarado PC; Pettie D; Collier JH Annu Rev Biomed Eng; 2024 Jul; 26(1):273-306. PubMed ID: 38959389 [TBL] [Abstract][Full Text] [Related]
35. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern. Al-Fattah Yahaya AA; Khalid K; Lim HX; Poh CL Viruses; 2023 Feb; 15(3):. PubMed ID: 36992333 [TBL] [Abstract][Full Text] [Related]
36. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955 [TBL] [Abstract][Full Text] [Related]
37. The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. Muhar BK; Nehira J; Malhotra A; Kotchoni SO J Pharm Pract; 2023 Aug; 36(4):953-966. PubMed ID: 35723017 [TBL] [Abstract][Full Text] [Related]
38. Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs. Mossadeq S; Shah R; Shah V; Bagul M AAPS PharmSciTech; 2022 Nov; 24(1):2. PubMed ID: 36416999 [TBL] [Abstract][Full Text] [Related]
39. Deciphering Vaccines for COVID-19: where do we stand today? Baviskar T; Raut D; Bhatt LK Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486 [TBL] [Abstract][Full Text] [Related]
40. COVID-19 mRNA vaccines: Platforms and current developments. Szabó GT; Mahiny AJ; Vlatkovic I Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]